Sie befinden sich hier

Inhalt

Science

INNOVATION. EXCELLENCE. INTERNATIONALITY

The overall goal of GRK 2727 is to uncover checkpoints in innate immune cells at the transcriptional, post- transcriptional, metabolic and cell-surface receptor levels, and to validate their functions in cancer and conditions of tissue damage.

Topics of GRK 2727:

We focus on Natural Killer (NK) cells and monocytes/macrophages that function at the forefront of immune responses. We expect that the obtained mechanistic knowledge will be instrumental for the design of innovative therapies of cancer and in conditions of tissue damage, where these checkpoints could be therapeutically blocked or fostered, respectively. Consortium members benefit from complementary expertise in innate immunity, a common focus on complex immune processes, and from sharing cutting-edge experimental methods including sophisticated single-cell RNAseq analyses, proteomics, metabolomics and multiparameter flow cytometry. Our goals are tackled by interdisciplinary collaborations of experts in different fields of innate immunity and with structured cooperations between basic and clinical researchers. To benefit from complementary expertise in innate immunity, GRK 2727 collaborates with pioneers in the field of innate immunity from the Karolinska Institute (KI) in Stockholm and Vienna University.

A: Cell intrinsic mechanisms of innate immune checkpoints

A.1: Gene expression checkpoints

A.2: Metabolic checkpoints

B: Modulation of innate immune reactivity in disease

B.1: Cancer

B.2: Damage

Kontextspalte

GRK 2727/1 InCheck
„Innate Immune Checkpoints in Cancer and Tissue Damage"

Ludolf-Krehl-Str. 13-17
68167 Mannheim
Phone +49 (0)621/383-71505
Fax +49 (0)621/383-71506
grk2727@remove-this.medma.uni-heidelberg.de
Twitter GRK 2727: @grk2727